Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Inventory (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Inventory for 4 consecutive years, with $10.2 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 60.5% to $10.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 60.5% year-over-year, with the annual reading at $10.2 million for FY2025, 60.5% up from the prior year.
  • Inventory for Q4 2025 was $10.2 million at Gyre Therapeutics, up from $8.9 million in the prior quarter.
  • The five-year high for Inventory was $10.2 million in Q4 2025, with the low at $4.3 million in Q4 2023.
  • Average Inventory over 4 years is $6.9 million, with a median of $6.4 million recorded in 2024.
  • The sharpest move saw Inventory tumbled 30.07% in 2023, then skyrocketed 60.5% in 2025.
  • Over 4 years, Inventory stood at $6.1 million in 2022, then crashed by 30.07% to $4.3 million in 2023, then surged by 48.03% to $6.3 million in 2024, then skyrocketed by 60.5% to $10.2 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $10.2 million, $8.9 million, and $8.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.